Increasing prevalence of diabetes is influencing demand of needle-free injection systems on account of administrating accurate dose of insulin. Furthermore, frequent monitoring of blood sugar with needles increases the risk of infection and pain among individuals. Moreover, surging demand and technological advancements in the field of pain-free and self-administration of drugs are propelling the growth of the market. For instance, in 2015, Zogenix launched DosePro, a needle-free medication transportation technology, which is a prefilled, single-use and disposable subcutaneous medicine transportation system for self-administration of liquid medicine formulations.
Increasing prevalence of infectious diseases such as hepatitis, dengue fever, neurological disorders, and AIDS virus via syringe is also encouraging the need for needle free injections. For instance, as per U.S. organization of HIV, about 36.9 million people were diagnosed with HIV infection worldwide.
The global needle free injection systems market was valued at around USD 9,166 million in 2017 and expected to grow at a CAGR of 16.0% in the forecast period.
The global needle free injection system market is segmented by product, technology, type of medication, usability, side of delivery, application and end users.
Based on product type, the market is segmented into fillable needle-free injectors and prefilled needle-free injectors.
On the basis of technology, the needle free injection system market is segmented into spring-based needle-free injectors, vibration-based needle-free injectors, laser-powered needle-free injectors, and jet-based needle-free injectors.
Based on the usability, the needle free injection system the market is segmented into disposable needle-free injectors and reusable needle-free injectors.
On the basis of type of medication, the needle free injection system market is segmented into
Projectile/depot-based needle free injectors, powder-based needle free injectors, and Liquid-based needle free injectors.
Based on the site of delivery, the market is segmented into intradermal injectors, intramuscular injectors, and subcutaneous injectors. Subcutaneous injectors segment is expected to dominate the market owing to the rising preference of patients towards self-administration of drugs.
Based on the application, the market is segmented into vaccine needle free delivery, pain management needle free delivery, oncology needle free delivery, insulin needle free delivery, and other applications.
Based on end user the market is segmented into clinics and hospital, home care settings, research laboratories, pharmaceutical and biotechnology companies and other end users.
Geographically, needle free injection system market is segmented into North America, Europe, Asia Pacific, Latin America and The Middle East & Africa (LAMEA).
North America is likely to hold the largest share in the global needle free injection system market during the forecast period. This is attributed to rising demand for vaccination in pediatric patient is increasing demand of market.
Europe is expected to be the second leading region in the global needle free injection system market. Increasing number of incidences of diabetes is propelling the growth of the needle-free insulin devices. For instance, according to World Health Organization, in 2014, around 422 million people suffered from diabetes in U.K.
Asia Pacific (APAC) is expected to be the fastest-growing region during the forecast period 2019–2026. This is attributed to increasing prevalence of chronic diseases and communicable diseases due to needlestick injuries in the region. Increasing prevalence of diabetes in India and China is boosting the growth of the market.
LAMEA is expected to witness sluggish growth in the global market during the forecast period. This is attributed to the poor healthcare infrastructure in Africa and slow growing economies. However, improving healthcare infrastructure, and high disposable income in the Middle East countries are driving the growth in the region.
Some of the key players in the global needle free injection market include Endo International plc, Antares Pharma, Inc., PenJet Corporation, Bioject Medical Technologies Inc., Medical International Technology, Inc., PharmaJet, National Medical Products Inc., Valeritas, Inc., INJEX Pharma AG, European Pharma Group and Crossject SA.
Our report covers the global TIC market insights, focusing on recent developments in the market in different regions and development strategies of the companies. Moreover, following sections are specifically covered in the report.